TriangleZanidatamab (NCT06695845)
Zanidatamab trial for Breast Cancer (NCT06695845). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with advanced HER2 IHC3-positive solid tumors after systemic treatment, with no remaining treatment of established benefit. Biliary cancers are excluded. Breast and gastroesophageal cohorts require prior trastuzumab deruxtecan; other tumors exclude previous HER2 therapy. Colorectal and lung cancers have additional mutation restrictions.
The idea: zanidatamab binds two HER2 sites, blocking growth signaling and recruiting immune attack. Patients receive intravenous treatment. Researchers measure tumor response, survival, and safety; central testing must confirm HER2 expression.
This phase 2 study plans 200 patients. Jazz Pharmaceuticals sponsors; five US sites recruit.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.